8-K - Prelude Therapeutics Incorporated | StockGist

Current Report Details

Event Type

Management Change+4 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. Exclusive Option Agreement On November 3, 2025, Prelude Therapeutics Incorporated (the “Company”) entered into an Ex

Material Agreement

$60.0M$35.0M$25.0M$100.0M

3.02

Unregistered Sales of Equity Securities. The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. Based in part upo

Securities Issuance

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 4,

Management Change

$750.00President and Chief Medical Officer of the CompanCompany on any matter relating to the Company

7.01

of this Current Report on Form 8-K and Exhibits 99.1, 99.2, and 99.3 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Ex

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release announcing Exclusive Option Agreement with Incyte, dated November 4,

Exhibits Only

Source Document

Exhibits (4)

8-K

Exhibit

99.1

PRESS RELEASE ANNOUNCING EXCLUSIVE OPTION AGREEMENT WITH INCYTE, DATED NOVEMBER 4, 2025

99.2

PRESS RELEASE ANNOUNCING STRATEGIC BUSINESS UPDATE, DATED NOVEMBER 4, 2025

99.3

CORPORATE PRESENTATION, DATED NOVEMBER 4, 2025